Rudat V, Vanselow B, Wollensack P, Bettscheider C, Osman-Ahmet S, Eble M J, Dietz A
Department of Radiation Oncology, University of Heidelberg, Im Neuenheimer Feld 400, D-69120, Hiedelberg, Germany.
Radiother Oncol. 2000 Oct;57(1):31-7. doi: 10.1016/s0167-8140(00)00200-0.
The purpose of this study was to evaluate the repeatability and the predictive relevance of the pretreatment pO(2) histography on the survival of patients with advanced head and neck cancer.
From July 1995 to August 1998, polarographic pO(2) measurements of lymph node metastases before therapy were performed in altogether 60 patients with histologically proven squamous cell carcinoma of the head and neck using the Eppendorf histograph. Forty-one of 60 patients were treated with an accelerated-hyperfractionated radiotherapy regimen with or without simultaneous chemotherapy as part of a multicenter phase III study. In 23 of 60 patients, two repeated independent measurements of the same tumor were performed with a time interval of approximately 24 h between the two measurements.
The multivariate analysis revealed the fraction of pO(2) values </=2.5 mmHg as the only significant prognostic factor for the survival (P=0.05) in the 41 study patients. No correlation was found between tumour oxygenation and the volume of the measured lymph node metastases or the haemoglobin concentration. The coefficient of variation of the repeated measurements representing the assay variability was 57-68% of the total variation.
Our data support the concept of the relevance of the pretreatment tumour hypoxia for the prognosis of patients with head and neck cancer after fractionated radiotherapy. Because of the relative poor repeatability of the pO(2) histography and the small patient number, further studies are required to confirm this finding and to evaluate the most relevant oxygenation parameter for clinical endpoints.
本研究旨在评估治疗前氧分压组织成像对晚期头颈癌患者生存情况的可重复性及预测相关性。
1995年7月至1998年8月,共60例经组织学证实为头颈鳞状细胞癌的患者,使用Eppendorf组织氧分压测定仪对治疗前淋巴结转移灶进行极谱法氧分压测量。60例患者中有41例作为多中心III期研究的一部分,接受了加速超分割放疗方案,联合或不联合同步化疗。60例患者中的23例,对同一肿瘤进行了两次重复独立测量,两次测量间隔约24小时。
多因素分析显示,在41例研究患者中,氧分压值≤2.5 mmHg的比例是生存的唯一显著预后因素(P = 0.05)。未发现肿瘤氧合与测量的淋巴结转移灶体积或血红蛋白浓度之间存在相关性。代表测定变异性的重复测量变异系数为总变异的57 - 68%。
我们的数据支持治疗前肿瘤缺氧与头颈癌患者分割放疗后预后相关性的概念。由于氧分压组织成像的可重复性相对较差且患者数量较少,需要进一步研究来证实这一发现,并评估对临床终点最相关的氧合参数。